Gilman Hill Asset Management LLC Has $9.75 Million Holdings in Pfizer Inc. $PFE

Gilman Hill Asset Management LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 0.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 402,079 shares of the biopharmaceutical company’s stock after purchasing an additional 3,663 shares during the quarter. Pfizer makes up about 1.6% of Gilman Hill Asset Management LLC’s investment portfolio, making the stock its 13th largest position. Gilman Hill Asset Management LLC’s holdings in Pfizer were worth $9,746,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter worth approximately $27,000. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth approximately $28,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer in the 4th quarter valued at $30,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PFE. Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Berenberg Bank lowered their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Price Performance

NYSE PFE opened at $23.88 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a market capitalization of $135.77 billion, a PE ratio of 12.70, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The firm’s 50 day moving average is $24.73 and its 200-day moving average is $24.25.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the business posted $0.60 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.